Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovavaxMEX:NVAX -1.25%45 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 45/100 and a GF Value™ of MXN67.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 376 Biotechnology companies, Novavax ranks worse than 96.54% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Novavax's
Operating Income
for the
three
months ended in Mar. 2026 was MXN-278 Mil. Novavax's Interest Expense for the
three
months ended in Mar. 2026 was MXN-88 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Novavax Incs earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
The historical rank and industry rank for Novavax's Interest Coverage or its related term are showing as below:
MEX:NVAX'
s Interest Coverage Range Over the Past 10 Years
Min: 0.91 Med: 24.42 Max: 24.42
Current: 0.91
MEX:NVAX's Interest Coverage is ranked worse than 96.54% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs MEX:NVAX: 0.91
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Novavax Interest Coverage Related Terms
Novavax Interest Coverage Historical Data
* Premium members only.
The historical data trend for Novavax's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:NVAX vs MPLT, COAG, INBX: Interest Coverage Comparison
For the Biotechnology subindustry, Novavax's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Novavax's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Novavax did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Novavax (MEX:NVAX) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novavax and its competitors. Over the past decade, Novavax's Interest Coverage has ranged from 0.91 to 24.42. According to the industry distribution chart, Novavax ranks #363 out of 376 companies in the Biotechnology industry, placing it in the top 96.5%.
Is Novavax's Interest Coverage too high?
Novavax's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 24.42. Based on the distribution chart, Novavax ranks #363 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Novavax has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Interest Coverage compare to MPLT and COAG?
According to the Biotechnology industry distribution chart, Novavax ranks #363 out of 376 companies for Interest Coverage. This places Novavax in the lower half of its industry. The industry median Interest Coverage is 104.03. Historically, Novavax's own Interest Coverage has ranged from 0.91 to 24.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novavax and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novavax's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN67.16, compared to a current price of MXN158.00 — trading 135.3% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Novavax's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (MEX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of MXN158.00 is trading 135.3% above its estimated GF Value™ of MXN67.16.
GuruFocus considers Novavax to be Significantly Overvalued.
Key valuation signals for MEX:NVAX:
Interest Coverage: 0 (At Loss)
GF Value™: MXN67.16 vs. price of MXN158.00 (135.3% above fair value)
No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
45GF Score
Get the complete analysis for MEX:NVAX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVAX has been successfully added to your 
